Thought Leadership

IntrinsiQ Specialty Solutions

Valuable insights from community physicians on emerging therapies

IntrinsiQ Specialty Solutions

July 2024

Leveraging longitudinal patient treatment patterns to determine appropriate physician education and marketing activities

IntrinsiQ Specialty Solutions

July 2021

Managing Through the Pandemic — How Analytics can Provide Greater Insights

IntrinsiQ Specialty Solutions

November 2020

The Value of Longitudinal Data During the Pandemic

IntrinsiQ Specialty Solutions

August 2020

Specialty Medications — Choosing the Right Strategic Partners

IntrinsiQ Specialty Solutions

May 2020

Clinical Trials During the COVID-19 Pandemic

IntrinsiQ Specialty Solutions

May 2020

Patient Recruitment in Clinical Trials Can be More Efficient

IntrinsiQ Specialty Solutions

January 2020

When is Longitudinal Data Important to Life Sciences Companies?

IntrinsiQ Specialty Solutions

September 2019

Moving Toward More Targeted Treatments in Specialty Care

IntrinsiQ Specialty Solutions

September 2019

The Complexities of Immunotherapy

IntrinsiQ Specialty Solutions

September 2019

3 Reasons Why Today’s Healthcare Data May Be Limiting Your View of Your Drug’s Market Potential

IntrinsiQ Specialty Solutions

August 2019

The Evolution of Cancer

IntrinsiQ Specialty Solutions

July 2019

Delivering Differentiated Clinical Education to Practices

IntrinsiQ Specialty Solutions

July 2019

Understanding Data's Value to Specialty Products

IntrinsiQ Specialty Solutions

June 2019

Rapid Advancements in Immunotherapy

IntrinsiQ Specialty Solutions

April 2019

Medication Adherence – What Data is Available to Provide Insight into Non-Compliance?

IntrinsiQ Specialty Solutions

November 2018

Pharmaceutical Companies Need Data to Improve Product Access and Utilization

IntrinsiQ Specialty Solutions

November 2018

The Changing Business Model

IntrinsiQ Specialty Solutions

October 2017

HHS Institutes Ruling for More Transparency in Clinical Trials

IntrinsiQ Specialty Solutions

April 2017

What Does Interoperability Mean to Patient Health?

IntrinsiQ Specialty Solutions

April 2017

Thought Leadership

Valuable insights from community physicians on emerging therapies

Confidently create your clinically driven GPO contracts with timely data

Finding the right subjects for your clinical trial enrollment

Time and resources spent recruiting qualified subjects for clinical trials

Where are the subjects for your clinical trials?

Engaging and educating the healthcare provider in the current environment

Leveraging longitudinal patient treatment patterns to determine appropriate physician education and marketing activities

Managing Through the Pandemic — How Analytics can Provide Greater Insights

The Value of Longitudinal Data During the Pandemic

Specialty Medications — Choosing the Right Strategic Partners

Clinical Trials During the COVID-19 Pandemic

Patient Recruitment in Clinical Trials Can be More Efficient

When is Longitudinal Data Important to Life Sciences Companies?

Moving Toward More Targeted Treatments in Specialty Care

The Complexities of Immunotherapy

3 Reasons Why Today’s Healthcare Data May Be Limiting Your View of Your Drug’s Market Potential

The Evolution of Cancer

Delivering Differentiated Clinical Education to Practices

Understanding Data's Value to Specialty Products

Rapid Advancements in Immunotherapy

Medication Adherence – What Data is Available to Provide Insight into Non-Compliance?

Pharmaceutical Companies Need Data to Improve Product Access and Utilization

The Changing Business Model

HHS Institutes Ruling for More Transparency in Clinical Trials

What Does Interoperability Mean to Patient Health?

Thought Leadership